Oporia Osteoporosis NDA Review Extended To September
This article was originally published in The Pink Sheet Daily
FDA's review of Pfizer's selective estrogen receptor modulator Oporia (lasofoxifene) for the treatment of osteoporosis has been extended until September
You may also be interested in...
The company says it will consider “various possible courses of action” following FDA’s decision on the selective estrogen receptor modulator.
ClinROs, artificial intelligence-based algorithms will be included in approval pathway. FDA is taking a crash course on new techniques for trial assessment thanks to COVID.